TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Public ClinicalTrials.gov record NCT04306900. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Study identification
- NCT ID
- NCT04306900
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 185 participants
Conditions and interventions
Conditions
Interventions
- TTX-030, budigalimab and mFOLFOX6 Combination Product
- TTX-030, budigalimab and docetaxel Combination Product
- TTX-030 and mFOLFOX6 Combination Product
- TTX-030 and budigalimab Combination Product
- TTX-030, budigalimab, nab-paclitaxel and gemcitabine Combination Product
- TTX-030 and pembrolizumab Combination Product
- TTX-030, nab-paclitaxel and gemcitabine Combination Product
- Budigalimab and mFOLFOX6 Combination Product
Combination Product
Eligibility (public fields only)
- Age range
- 18 Years to 110 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2020 (Actual)
- Primary completion
- Nov 30, 2022 (Actual)
- Completion
- Mar 27, 2024 (Actual)
- Last update posted
- Jul 29, 2025
2020 – 2024
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute | Scottsdale | Arizona | 85258 | — |
| City of Hope Medical Center Clinical Trials Office | Duarte | California | 91010 | — |
| University of Southern California | Los Angeles | California | 90007 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| UCLA Hematology/Oncology | Los Angeles | California | 90404 | — |
| Chao Family Comprehensive CC, UCI | Orange | California | 92868 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine | Miami | Florida | 33136 | — |
| Ocala Oncology Center PL | Ocala | Florida | 34474 | — |
| Orlando Health UF Health Cancer Center | Orlando | Florida | 32835 | — |
| IACT Health - John B. Amos Cancer Center | Columbus | Georgia | 31904 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | — |
| Nebraska Cancer Center Oncology Hematology West P.C. | Omaha | Nebraska | 68130 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44122 | — |
| University of Toledo | Toledo | Ohio | 43614 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Prisma-Health Cancer Institute | Greenville | South Carolina | 29605 | — |
| West Cancer Center and Research Institute | Germantown | Tennessee | 38138 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
| Hunstman Cancer Intitute | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Froedtert Hospital & Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04306900, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2025 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04306900 live on ClinicalTrials.gov.